BRAF and acute myeloid leukemia: Importantly, in the literature, one patient with BRAF V600E-mutated AML demonstrated a dramatic but transient response to combination therapy with the BRAF inhibitor ‘dabrafenib’ and the MEK inhibitor ‘trametinib’ [1].